Antiphospholpid Syndrome: Risk Factor for Preeclampsia
Publish place: 7th International Conference on New Findings in Midwifery, Obstetrics, Gynecology and Infertility
Publish Year: 1401
Type: Conference paper
Language: English
View: 327
This Paper With 10 Page And PDF Format Ready To Download
- Certificate
- I'm the author of the paper
Export:
Document National Code:
ICMWMI07_050
Index date: 7 August 2022
Antiphospholpid Syndrome: Risk Factor for Preeclampsia abstract
Antiphospholipid syndrome is the most frequently acquired risk factor for a treatable cause of recurrent abortion, stillbirth, preeclampsia, intrauterine death, premature birth, and fetal growth restriction. The purpose of this study was to review current literature about the antiphospholipid syndrome as a risk factor for preeclampsia. Systematic literature searches using pre-specified terms were performed on PubMed, Ovid EMBASE, Ovid Medline, Cochrane library, Clinicaltrials.gov, and Web of Science from database inception dates to Jun 2022. Antiphospholipid syndrome, in relation to pregnancy, is characterized by the presence of antiphospholipid autoantibodies in association with repeated fetal loss and complications such as preeclampsia retarded fetal growth, or placental insufficiency.
Antiphospholpid Syndrome: Risk Factor for Preeclampsia Keywords:
Antiphospholpid Syndrome: Risk Factor for Preeclampsia authors
Mahmood Abedinzade
Associate Professor, Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
Zahra Bostani Khalesi
Associate Professor, Department of Midwifery, School of Nursing and Midwifery, Guilan University of Medical Sciences, Rasht, Iran